Kyle D. Kuvalanka
2016
In 2016, Kyle D. Kuvalanka earned a total compensation of $495.3K as Chief Operating Officer at Syros Pharmaceuticals, a 67% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $115,045 |
|---|---|
| Salary | $380,000 |
| Other | $270 |
| Total | $495,315 |
Kuvalanka received $380K in salary, accounting for 77% of the total pay in 2016.
Kuvalanka also received $115K in non-equity incentive plan and $270 in other compensation.
Rankings
In 2016, Kyle D. Kuvalanka's compensation ranked 11,213th out of 14,075 executives tracked by ExecPay. In other words, Kuvalanka earned more than 20.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 11,213 out of 14,075 | 20th |
Division Manufacturing | 4,355 out of 5,489 | 21st |
Major group Chemicals And Allied Products | 1,558 out of 1,895 | 18th |
Industry group Drugs | 1,257 out of 1,538 | 18th |
Industry Pharmaceutical Preparations | 979 out of 1,176 | 17th |
Source: SEC filing on April 25, 2017.
Kuvalanka's colleagues
We found three more compensation records of executives who worked with Kyle D. Kuvalanka at Syros Pharmaceuticals in 2016.